Second Danish deal for Sareum Holdings
Sareum Holdings, a specialist structure-based drug discovery business, has entered into a second collaborative agreement with H. Lundbeck A/S (Copenhagen: LUN), an international pharmaceutical company with sales of around 1.2 billion Euros in 2005, to provide protein structure determination capabilities to accelerate drug discovery research at Lundbeck. Sareum will apply its skills in high throughput protein expression, purification and structure determination to help Lundbeck scientists develop new and improved therapeutics to assist patients suffering from diseases of the central nervous system – Lundbeck’s key drug discovery focus area.
In return, Sareum will receive research fees and success milestone payments.
Financial terms of the agreement have not been disclosed.